Fineline Cube

Follow:
14778 Articles
VFLO Medical Partners with Inari Medical to Expand Access in Greater China
CompanyDeals

VFLO Medical Partners with Inari Medical to Expand Access in Greater China

Uni-Bio Science Group Achieves Milestones in Medical Aesthetics with New Product Approvals
CompanyDrug

Uni-Bio Science Group Achieves Milestones in Medical Aesthetics with New Product Approvals

Ocumen Therapeutics' OT-301 Phase III Denali Study Surpasses 140 Patient Enrollment in China
CompanyDrug

Ocumen Therapeutics’ OT-301 Phase III Denali Study Surpasses 140 Patient Enrollment in China

China Medical System Holdings Secures Exclusive Rights to Atom Therapeutics' Gout Drug ABP-671
CompanyDeals

China Medical System Holdings Secures Exclusive Rights to Atom Therapeutics’ Gout Drug ABP-671

Novartis Secures Global Rights to PTC Therapeutics' Huntington's Disease Treatment PTC518
CompanyDeals

Novartis Secures Global Rights to PTC Therapeutics’ Huntington’s Disease Treatment PTC518

UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China
CompanyDeals

UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China

Minghui Pharmaceutical's MH004 Ointment Meets Primary Endpoints in Atopic Dermatitis Phase III Study
CompanyDrug

Minghui Pharmaceutical’s MH004 Ointment Meets Primary Endpoints in Atopic Dermatitis Phase III Study

China's NHC Launches Pilot Plan to Expand Wholly Foreign-Owned Hospital Sector
Policy / Regulatory

China’s NHC Launches Pilot Plan to Expand Wholly Foreign-Owned Hospital Sector

Hua Medicine's Second-Generation GKA HM-002-1005 Completes Phase Ia Study in the US
CompanyDrug

Hua Medicine’s Second-Generation GKA HM-002-1005 Completes Phase Ia Study in the US

Shanghai MicuRx's MRX-4/Contezolid Meets Primary Endpoint in Phase III cSSTI Study
CompanyDrug

Shanghai MicuRx’s MRX-4/Contezolid Meets Primary Endpoint in Phase III cSSTI Study

CBC Group and Mubadala Acquire UCB's Neurology and Allergy Business in China for $680 Million
CompanyDeals

CBC Group and Mubadala Acquire UCB’s Neurology and Allergy Business in China for $680 Million

Simcere Zaiming Launches Phase III Trial for SERD Inhibitor SIM0270 in Breast Cancer
CompanyDrug

Simcere Zaiming Launches Phase III Trial for SERD Inhibitor SIM0270 in Breast Cancer